NRC
National Research Corporation18.43
+0.43+2.39%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
425.06MP/E (TTM)
25.96Basic EPS (TTM)
0.71Dividend Yield
0.03%Recent Filings
10-Q
Q3 FY2025 results
NRC Health posted Q3 revenue of $34.6M, down 3% y/y yet holding operating income steady at $7.7M with margins firm at 22% as direct expenses plunged 19% from lower conferences and workforce cuts. Operating income dipped to $17.9M YTD (down 30% y/y) on SG&A jumps from executive comp, while diluted EPS fell to $0.18 from $0.24 (reconciles to 22.1M shares; anti-dilution from 553k options). Cash fell to $2.2M amid $19.3M operating cash flow, $9.6M capex, $20.2M buybacks, and $8.3M dividends, but $80.4M Delayed Draw Term Loan (6.63%, due 2030) leaves $30M revolver and $27.6M term availability intact; covenants met. New CFO joined September 29. Client non-renewals pressure growth.
8-K
Q3 TRCV up 8%, cash flow soars
NRC Health reported Q3 revenue of $34.6 million, down from $35.8 million last year, yet TRCV surged 8% to $141.7 million on strong sales and retention. Cash flow from operations jumped 46% to $13.8 million. Adjusted EBITDA hit $10.9 million, up 11%. Board hiked quarterly dividend 33% to $0.16 per share.
8-K
CFO Appointment Announced
National Research Corporation appointed Shane Harrison as Executive Vice President and Chief Financial Officer, effective September 25, 2025, succeeding Michael D. Hays as principal financial officer. Harrison brings 25 years of finance expertise from PowerSchool, NAVEX Global, and FLIR Systems, with a compensation package including $400,000 base salary, $100,000 signing bonus, and 172,000 restricted shares vesting over three years. This leadership shift aims to drive growth and profitability. Forward-looking statements highlight potential risks from uncertainties.
10-Q
Q2 FY2025 results
National Research Corporation's Q2 revenue dipped 3% year-over-year to $34.0M, driven by a $1.3M drop in recurring revenue from existing clients, yet sequential gains in total recurring contract value signal stabilizing demand. Operating income plunged 82% to $1.6M amid $6.6M in executive cash bonuses and elevated share-based compensation, pushing SG&A up 58% and shrinking margins to 5%; net loss hit $0.1M or $(0.01) per diluted share on 22.7M shares, with anti-dilution from 403K options. Free cash flow wasn't disclosed in the 10-Q. Cash stood at $5.3M with $30M revolver availability and $27.6M untapped on the $110M delayed draw term loan maturing 2030 at 6.67%, funding $10.9M share repurchases and $5.5M dividends while compliant with covenants. The Nobl acquisition added intangible amortization but no fresh goodwill. New CEO Trent Green took helm June 1. Yet competition in healthcare analytics remains fierce.
8-K
Q2 revenue dips, TRCV grows
NRC Health reported Q2 2025 revenue of $34.0 million, down from $35.0 million last year, with a net loss of $0.1 million due to $6.6 million in non-recurring executive compensation from the CEO transition. Yet TRCV grew 2% sequentially, marking the third straight quarter of gains from stronger sales and retention. Adjusted EBITDA hit $10.3 million at 30.3% margin. The board declared a $0.12 quarterly dividend; repurchases returned $16.1 million YTD.
IPO
Website
Employees
Sector
Industry
CNXC
Concentrix Corporation
39.45+0.67
DH
Definitive Healthcare Corp.
2.29-0.01
FORA
Forian Inc.
2.14+0.00
HCAT
Health Catalyst, Inc
2.44+0.09
HSTM
HealthStream, Inc.
23.91-0.47
LNC
Lincoln National Corporation
45.30+0.10
NHC
National HealthCare Corporation
138.93-0.94
NUTX
Nutex Health Inc.
171.72-4.06
SYRA
Syra Health Corp.
0.07+0.01
WORX
SCWorx Corp.
0.21-0.01